Berry Genomics Launches Mobile Nucleic Acid Testing Laboratory to Support Routine Epidemic Prevention and Control

Recently, in active response to the State Council’s “Notice on Further Improving COVID-19 Testing During the Epidemic,” Berry Genomics has leveraged its technical strengths and experience in COVID-19 testing to lead the design and launch of a “Mobile Nucleic Acid Testing Laboratory.” This laboratory is suitable for nucleic acid testing of various pathogenic microorganisms, including SARS-CoV-2. Furthermore, it offers customized comprehensive solutions tailored to the specific needs of client institutions, covering experimental workflow design, laboratory deployment, training of professional technical personnel, qualification application, and data platform integration.

Berry Genomics Mobile Nucleic Acid Testing Laboratory

This new mobile laboratory technically complies with current regulatory standards, meeting Biosafety Level 2 (BSL-2) or higher requirements. The laboratory maintains negative pressure and fully satisfies the needs for nucleic acid testing of various microorganisms, including the novel coronavirus. Additionally, it enables high-throughput sequencing of unknown pathogenic microorganisms to decode their genomic sequences.

Currently, nucleic acid testing laboratories in hospitals at all levels, disease control and prevention institutions, and high-throughput entities such as customs are typically retrofitted within existing buildings. These projects often face challenges including prolonged renovation cycles, stringent spatial requirements, and significant contamination risks. Berry Genomics’ mobile nucleic acid testing laboratory redefines the operational paradigm of microbiological testing facilities. Featuring short transport distances, low risk of cross-infection, rapid and flexible deployment, and 5G-enabled big data transmission, it effectively addresses the difficulties associated with laboratory retrofitting and provides robust support for routine epidemic prevention and control in the post-pandemic era.

Short transport distance to avoid potential transmission risks. Mobile nucleic acid testing laboratories can be flexibly deployed at designated locations, enabling immediate sample collection and rapid report generation, with testing completed within three hours after sampling. This approach mitigates the potential risk of transmission associated with multiple sample transports.

Low Risk of Cross-Infection Due to Structural Independence. The mobile laboratory is completely independent from other buildings, enabling physical spatial segregation. This prevents secondary or multiple viral transmissions caused by overlaps in public areas and interconnected ventilation systems, thereby further averting cluster outbreaks.

Big Data 5G Transmission Ensures Real-Time Monitoring. The laboratory is equipped with an intelligent management system, enabling 5G transmission of test data to ensure efficient real-time monitoring and data feedback.

Rapid and Flexible Deployment, Robustly Safeguarding National Biosecurity. As a strategic reserve for routine epidemic prevention and control, mobile nucleic acid testing laboratories can be rapidly deployed at the earliest opportunity in the event of an outbreak involving unknown microorganisms. They enable immediate deciphering of microbial sequences and development of nucleic acid testing kits, thereby providing strong assurance for national biosecurity.

Since the outbreak of the epidemic this year, Berry Genomics, as the primary provider of novel coronavirus (SARS-CoV-2) nucleic acid testing in Fuzhou City, has developed an efficient “comprehensive solution for SARS-CoV-2 screening and testing.” In collaboration with Mengchao Hepatobiliary Hospital of Fujian Medical University, it established a “Novel Coronavirus Testing Laboratory” to conduct tests on confirmed cases, suspected cases, close contacts, and individuals under medical observation in Fuzhou. Subsequently, Berry Genomics undertook the task of conducting SARS-CoV-2 nucleic acid testing for employees returning to work in Fuzhou, with a daily testing capacity exceeding 10,000 samples. To date, it has provided testing services to more than 8,000 enterprises and organizations across the city, with a cumulative total of over 300,000 tests performed. Furthermore, as the epidemic spread globally, Berry Genomics assumed full responsibility for nucleic acid testing of inbound personnel entering Fuzhou from abroad.